ATE131723T1 - Liposomenhaltige intranasale impfstofformulierung - Google Patents

Liposomenhaltige intranasale impfstofformulierung

Info

Publication number
ATE131723T1
ATE131723T1 AT91200142T AT91200142T ATE131723T1 AT E131723 T1 ATE131723 T1 AT E131723T1 AT 91200142 T AT91200142 T AT 91200142T AT 91200142 T AT91200142 T AT 91200142T AT E131723 T1 ATE131723 T1 AT E131723T1
Authority
AT
Austria
Prior art keywords
liposome
vaccine formulation
intranasal vaccine
containing intranasal
formulation
Prior art date
Application number
AT91200142T
Other languages
German (de)
English (en)
Inventor
De Haan Aalzen
Geerligs J Harmen
Jan C Wilschut
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res filed Critical Duphar Int Res
Application granted granted Critical
Publication of ATE131723T1 publication Critical patent/ATE131723T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT91200142T 1990-01-29 1991-01-25 Liposomenhaltige intranasale impfstofformulierung ATE131723T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9000207A NL9000207A (en:Method) 1990-01-29 1990-01-29

Publications (1)

Publication Number Publication Date
ATE131723T1 true ATE131723T1 (de) 1996-01-15

Family

ID=19856496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91200142T ATE131723T1 (de) 1990-01-29 1991-01-25 Liposomenhaltige intranasale impfstofformulierung

Country Status (15)

Country Link
US (1) US5756104A (en:Method)
EP (1) EP0440289B1 (en:Method)
JP (1) JP2997073B2 (en:Method)
AT (1) ATE131723T1 (en:Method)
AU (1) AU647070B2 (en:Method)
CA (1) CA2035097A1 (en:Method)
DE (1) DE69115514T2 (en:Method)
DK (1) DK0440289T3 (en:Method)
ES (1) ES2082107T3 (en:Method)
GR (1) GR3019213T3 (en:Method)
HU (1) HUT61204A (en:Method)
IE (1) IE74950B1 (en:Method)
IL (1) IL97014A (en:Method)
NL (1) NL9000207A (en:Method)
ZA (1) ZA91531B (en:Method)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4136553A1 (de) * 1991-11-06 1993-05-13 Biotechnolog Forschung Gmbh Impfstoff gegen schleimhauterreger und herstellungsverfahren
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
EP1013269A4 (en) * 1997-06-06 2002-02-20 Shionogi & Co IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SI1031347T1 (en) * 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en) * 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
KR20040073438A (ko) * 2001-11-19 2004-08-19 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
CN101107009B (zh) 2005-01-20 2014-08-06 伊斯克诺瓦公司 包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
ES2272178B1 (es) * 2005-09-19 2008-03-16 Daniel Serrano Gil Una composicion para ser administrada a un mamifero o a un ser humano.
US20080033038A1 (en) * 2006-07-07 2008-02-07 Shytle R D Compositions of polyphenols and methods of use
SI2861214T1 (sl) * 2012-06-14 2021-01-29 Universitaet Bern Po meri narejeni liposomi za zdravljenje bakterijskih infekcij
ES2442450B1 (es) * 2012-08-09 2014-12-12 Enoc Solutions, S.L. Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional
WO2015031536A1 (en) 2013-08-27 2015-03-05 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4323561A (en) * 1977-09-06 1982-04-06 Temple University Of The Commonwealth System Of Higher Education Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4310550A (en) * 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
HU184141B (en) * 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4684625A (en) * 1982-07-08 1987-08-04 Syntex (U.S.A.) Inc. Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
DE3410238A1 (de) * 1984-03-21 1985-10-03 Bayer Ag, 5090 Leverkusen Glycolipid-aehnliche substanzen in liposomenform
DE3412793A1 (de) * 1984-04-05 1985-10-17 Basotherm GmbH, 7950 Biberach Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
FR2624741B1 (fr) * 1987-12-21 1991-06-28 Pasteur Institut Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability

Also Published As

Publication number Publication date
NL9000207A (en:Method) 1991-08-16
EP0440289A1 (en) 1991-08-07
ZA91531B (en) 1991-10-30
HU910256D0 (en) 1991-08-28
GR3019213T3 (en) 1996-06-30
DE69115514T2 (de) 1996-06-05
IE910268A1 (en) 1991-07-31
CA2035097A1 (en) 1991-07-30
AU647070B2 (en) 1994-03-17
IE74950B1 (en) 1997-08-13
IL97014A0 (en) 1992-03-29
HUT61204A (en) 1992-12-28
US5756104A (en) 1998-05-26
JP2997073B2 (ja) 2000-01-11
JPH04210925A (ja) 1992-08-03
AU6999091A (en) 1991-08-01
DE69115514D1 (de) 1996-02-01
IL97014A (en) 1995-01-24
EP0440289B1 (en) 1995-12-20
DK0440289T3 (da) 1996-03-04
ES2082107T3 (es) 1996-03-16

Similar Documents

Publication Publication Date Title
ATE131723T1 (de) Liposomenhaltige intranasale impfstofformulierung
NO945003D0 (no) Vaksineblanding inneholdende adjuvanser
PT748213E (pt) Metodos e composicoes para administracao pulmonar de insulina
DE69133314D1 (de) Aerosolzubereitungen zur dosierten Abgabe
FI931169A7 (fi) Parannetut rokotekoostumukset
ES2084360T3 (es) Formulaciones de aerosoles exentas de clorofluorocarbonos.
DE69110785D1 (de) Narkosemittelverdampfer.
DK1126874T5 (da) Multikomponent Meningococcus Vaccine
EP0734710A3 (en) Medicament and support
NL193899B (nl) Ademhalingsbedekking, zoals een gasmasker.
EP0437729A3 (en) New peptides, procedure for their preparation and their use as a medicament, especially their use as medicament against retroviruses
FI102169B (fi) 3-aminopyrrolit, menetelmä niiden valmistamiseksi ja niiden käyttö lää keaineina
DE59203456D1 (de) Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung.
DE3865818D1 (de) Arzneizubereitung fuer inhalatorische anwendungen.
ES2065434T3 (es) Utilizacion de aerosoles que contienen citocinas y aerosoles que contienen citocinas propiamente dichos.
EP0565708A4 (en) VACCINES USING LIPOSOMES, USED AGAINST MUCOSUS PATHOGENS.
DE59309355D1 (de) Neue Phospholipidderivate
FR2671974B1 (en:Method)
DE69131521D1 (de) Alpha-Ergocryptine enthaltende pharmazeutische Zusammensetzungen mit nervenschützender Wirkung
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
DK491189A (da) Respirator
IT9003745A0 (it) Ago a farfalla di sicurezza per uso medicale.
GB9006450D0 (en) Inhalation formulation
EP0537591A3 (en) Process for the preparation of 1,2-bis-(2-nitrophenoxy)-ethane
DK250890D0 (da) Canister til inhalationsmedicin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time